| Identifying predictive markers of chemosensitivity of breast cancer with random forests |
| Wei Hu |
| Reference |
|
| [1] | Nguyen, P. L., Taghian, A. G. et al. (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy, J. Clin Oncol., 26(14), 2373-8. | | | [2] | Perou, C. M., Sorlie, T., et al. (2000)Molecular portraits of human breast tumours, Nature, 406(6797), 747-752. | | | [3] | Sorlie, T., Perou, C. M. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98(19), 10869-10874. | | | [4] | Kapp, A. V., Jeffrey, S. S. et al. (2006) Discovery and validation of breast cancer subtypes. BMC Genomics, 7, 231. | | | [5] | Pusztai, L., (2008) Current status of prognostic profiling in breast cancer, The Oncologist, 13, 350-360. | | | [6] | van ’t Veer, L. J., Dai, H., et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536. | | | [7] | van de Vijver, M. J. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347, 1999-2009. | | | [8] | Ayers, M., Symmans, W. F., Stec, J. et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol, 22, 2284-2293. | | | [9] | Hess, K. R., Anderson, K., Symmans, W. F. et al., (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol, 24, 4236-4244. | | | [10] | Brenton, J. D., Carey L. A., Ahmed, A. A. et al. (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350-7360. | | | [11] | Wang, Y., Klijn, J. G. et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, 365, 671-679. | | | [12] | Ma, X. J., Wang, Z., et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 5(6), 607-16. | | | [13] | Brennan, K. and Anthony Brown, M. C. (2003) Is there a role for Notch signalling in human breast cancer? Breast Cancer Res, 5(2), 69-75. | | | [14] | Stylianou, S., Clarke, R. B. et al. (2006) Activation of notch signaling in human breast cancer, Cancer Research, 66, 1517-1525. | | | [15] | GEArray, O. Human notch signaling pathway microarray. http://www.sabiosciences.com/gene_array_product/HTML/OHS-059.html | | | [16] | Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol, 57, 289-300. | | | [17] | Pounds, S. and Morris, S. W. (2003) Estimating the occurrence of false positive and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19, 1236- 1242. | | | [18] | Breiman, L. and Random, F. (2001) Machine Learning, 45 (1), 5-32. | | | [19] | Díaz-Uriarte, R. and Alvarez de Andrés, S. (2006) Gene selection and classification of microarray data using random forest. BMC Bioinformatics, 7(3). | | | [20] | Rouzier, R., Rajan, R., et al. (2005) Microtubule associated protein tau is a predictive marker and modulator of response to paclitaxel-containing preoperative chemotherapy in breast cancer. Proc Natl Acad Sci U S A, 102, 8315-8320. | | | [21] | Ou, Y. H., Chung, P. H., et al. (2007)The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1, The EMBO Journal, 26, 3968-3980. | |
|